219 related articles for article (PubMed ID: 9555153)
1. [Value of determining serum cholesterol levels in patients with coronary heart disease].
Stalenhoef AF
Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2545-8. PubMed ID: 9555153
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
[TBL] [Abstract][Full Text] [Related]
3. Statins in the prevention of coronary heart disease.
Williamson DR; Pharand C
Pharmacotherapy; 1998; 18(2):242-54. PubMed ID: 9545143
[TBL] [Abstract][Full Text] [Related]
4. Prevention of mortality from coronary heart disease with pravastatin.
Tonkin AM; Ryan EW
Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
[TBL] [Abstract][Full Text] [Related]
5. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
6. Lowering cholesterol levels in patients with coronary heart disease. The LIPID Study Management Committee.
Med J Aust; 1995 May; 162(9):455-6. PubMed ID: 7746199
[No Abstract] [Full Text] [Related]
7. [Why the cardiologists should be interested in lipids?].
López-Sendón JL; Rubio R; López de Sá E; Delcán JL
Rev Esp Cardiol; 1995; 48 Suppl 2():23-32. PubMed ID: 7569272
[TBL] [Abstract][Full Text] [Related]
8. [Optimal lipid lowering therapy for coronary heart diseases patients in secondary prevention: moderate or aggressive LDL decrease preferred?].
MMW Fortschr Med; 2006 Nov; 148(48):54-5. PubMed ID: 17615773
[No Abstract] [Full Text] [Related]
9. [Therapeutic influence on the blood lipids in manifest coronary sclerosis].
Aschenbeck G
Rev Bras Med; 1971 Dec; 28(12):653-8. PubMed ID: 4259647
[No Abstract] [Full Text] [Related]
10. Lipid lowering agents. How important are they in secondary prevention of coronary heart disease?
Colquhoun DM
Aust Fam Physician; 2002 Jan; 31(1):25-6, 29-30. PubMed ID: 11840884
[TBL] [Abstract][Full Text] [Related]
11. Aggressive lipid-lowering therapy: a clinical imperative.
Pedersen TR
Eur Heart J; 1998 Oct; 19 Suppl M():M15-21. PubMed ID: 9821012
[TBL] [Abstract][Full Text] [Related]
12. Rational prescribing of statins.
Purcell H; Daly C; Sheppard M; Morrell J
Practitioner; 2001 Nov; 245(1628):957-9, 962-3. PubMed ID: 11727350
[No Abstract] [Full Text] [Related]
13. [Coronary heart disease prevention. Are there differences in cholesterol synthesis inhibitors?].
Müller-Wieland D; Faust M; Schleifenbaum T; Krone W
MMW Fortschr Med; 2000 Jul; 142(30):26-8. PubMed ID: 10955015
[TBL] [Abstract][Full Text] [Related]
14. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
[TBL] [Abstract][Full Text] [Related]
15. [Statins in primary prevention of coronary heart disease].
Paulweber B
Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
[TBL] [Abstract][Full Text] [Related]
16. [The role of cholesterol-lowering drugs in prevention of coronary heart disease].
Skałuba Z; Undas R
Przegl Lek; 1998; 55(7-8):382-7. PubMed ID: 10021881
[TBL] [Abstract][Full Text] [Related]
17. A clinical focus on statins.
Auer J; Eber B
Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
[TBL] [Abstract][Full Text] [Related]
18. Clinical prevention of coronary heart disease through cholesterol-lowering therapy.
Grundy SM
Curr Ther Endocrinol Metab; 1997; 6():520-6. PubMed ID: 9174799
[No Abstract] [Full Text] [Related]
19. [60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
MMW Fortschr Med; 2001 Nov; 143(44):60. PubMed ID: 11732408
[No Abstract] [Full Text] [Related]
20. [The effect of ethyl-chlorophenoxyisobutyrate on the serum lipids in coronary sclerosis].
Keller L; Rétsági G; Sebestyén M; Diczendy S; Erdélyi G
Z Gesamte Inn Med; 1966 Mar; 21(6):169-72. PubMed ID: 5988081
[No Abstract] [Full Text] [Related]
[Next] [New Search]
